Amanote Research
Register
Sign In
Pcn153 - Cost-Effectiveness Analysis of Apalutamide for Treatment in Non- Metastasis Castration-Resistant Prostate Cancer
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.236
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
Z. Zhou
X. Hu
Publisher
Elsevier BV
Related search
Apalutamide for the Treatment of Non‐metastatic Prostate Cancer
Prescriber
Pharmacology
Cost-Effectiveness Analyses and Cost Analyses in Castration-Resistant Prostate Cancer: A Systematic Review
PLoS ONE
Multidisciplinary
Pcn346 - Disease Specific Cost Analysis of the Nonmetastatic Castration-Resistant Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer Health States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn37 - Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Treatment Patterns of Castration Resistant Prostate Cancer in Japan
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Initial Experience of the Enzalutamide Treatment for Castration-Resistant Prostate Cancer
Japanese Journal of Urology
Urology
Visceral Disease in Castration-Resistant Prostate Cancer
European Urology
Urology
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Yearbook of Paediatric Endocrinology
The Addition of Apalutamide to ADT in the Treatment of Metastatic Castration-Sensitive Prostate Cancer: Safety and Efficacy
Expert Review of Anticancer Therapy
Oncology
Pharmacology
